Sean F. Scanlan - 10 Jan 2022 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role: SVP, Marketing
Signature: /s/ Lisa Taylor as Attorney-in-fact for Sean Scanlan
Issuer symbol: TMCI
Transactions as of: 10 Jan 2022
Net transactions value: -$889,824
Form type: 4
Filing time: 12 Jan 2022, 19:01:18 UTC
Previous filing: 05 Jan 2022
Next filing: 10 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TMCI	Common Stock	Options Exercise	$12,923	+8,231		$1.57^*	8,231	10 Jan 2022	Direct	F1
transaction	TMCI	Common Stock	Options Exercise	$48,091	+30,631	+372%	$1.57^*	38,862	10 Jan 2022	Direct	F1
transaction	TMCI	Common Stock	Sale	$783,532	-38,862	-100%	$20.16	0	10 Jan 2022	Direct	F1, F2
transaction	TMCI	Common Stock	Options Exercise	$3,806	+2,424		$1.57^*	2,424	11 Jan 2022	Direct	F1
transaction	TMCI	Common Stock	Options Exercise	$6,735	+6,414	+265%	$1.05^*	8,838	11 Jan 2022	Direct	F1
transaction	TMCI	Common Stock	Sale	$177,846	-8,838	-100%	$20.12	0	11 Jan 2022	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TMCI	Stock Option (Right to Buy)	Options Exercise	$0	-8,231	-15%	$0.000000	46,993	10 Jan 2022	Common Stock	8,231	$1.57	Direct	F1, F4
transaction	TMCI	Stock Option (Right to Buy)	Options Exercise	$0	-30,631	-46%	$0.000000	36,244	10 Jan 2022	Common Stock	30,631	$1.57	Direct	F1, F5
transaction	TMCI	Stock Option (Right to Buy)	Options Exercise	$0	-2,424	-6.7%	$0.000000	33,820	11 Jan 2022	Common Stock	2,424	$1.57	Direct	F1, F5
transaction	TMCI	Stock Option (Right to Buy)	Options Exercise	$0	-6,414	-3.6%	$0.000000	174,149	11 Jan 2022	Common Stock	6,414	$1.05	Direct	F1, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2	The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.62 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.34 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4	The stock option is partially vested and will vest with respect to the remaining shares in equal annual installments, so that the options will be fully vested on April 23, 2023.
F5	The stock option is partially vested and will vest with respect to the remaining shares in equal annual installments, so that the options will be fully vested on January 22, 2023.
F6	The stock option is partially vested and will vest with respect to the remaining shares in equal annual installments, so that the options will be fully vested on January 23, 2022.